During the last session, Adma Biologics Inc (NASDAQ:ADMA)’s traded shares were 2.33 million, with the beta value of the company hitting 0.62. At the end of the trading day, the stock’s price was $16.96, reflecting an intraday gain of 1.50% or $0.25. The 52-week high for the ADMA share is $21.13, that puts it down -24.59 from that peak though still a striking 80.96% gain since the share price plummeted to a 52-week low of $3.23. The company’s market capitalization is $3.95B, and the average intraday trading volume over the past 10 days was 2.95 million shares, and the average trade volume was 5.18 million shares over the past three months.
Adma Biologics Inc (ADMA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ADMA has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.13.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adma Biologics Inc (NASDAQ:ADMA) trade information
Adma Biologics Inc (ADMA) registered a 1.50% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.50% in intraday trading to $16.96, hitting a weekly high. The stock’s 5-day price performance is 8.09%, and it has moved by -14.21% in 30 days. Based on these gigs, the overall price performance for the year is 413.94%. The short interest in Adma Biologics Inc (NASDAQ:ADMA) is 16.07 million shares and it means that shorts have 2.09 day(s) to cover.
The consensus price target of analysts on Wall Street is $16, which implies a decrease of -6.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $14 and $18 respectively. As a result, ADMA is trading at a discount of -6.13% off the target high and 17.45% off the low.
Adma Biologics Inc (ADMA) estimates and forecasts
Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 1,200.00% this quarter and then jump 275.00% in the quarter after that. In the rating firms’ projections, revenue will increase 57.30% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 105.85M as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 110.7M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 38.68%. While earnings are projected to return 471.15% in 2024.
ADMA Dividends
Adma Biologics Inc is due to release its next quarterly earnings in November. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Adma Biologics Inc (NASDAQ:ADMA)’s Major holders
Adma Biologics Inc insiders own 2.58% of total outstanding shares while institutional holders control 82.71%, with the float percentage being 84.91%. BLACKROCK INC. is the largest shareholder of the company, while 358.0 institutions own stock in it. As of 2024-06-30, the company held over 18.64 million shares (or 8.1462% of all shares), a total value of $208.45 million in shares.
The next largest institutional holding, with 14.52 million shares, is of VANGUARD GROUP INC’s that is approximately 6.3426% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $162.3 million.
